-
07:01:02 PM

BMY Stock News

03/20/23 7:00 AM
NYSE : BMY
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
CHARM Therapeutics, a 3 D deep learning biotechnology company discovering and developing transformational medicines, today announced a strategic discovery collaboration with Bristol Myers Squibb for the identification and optimisation of compounds against Bristol Myers Squibb selected targets. “CHARM is excited to collaborate with Bristol Myers...
RHEA-AI
neutral
03/15/23 6:59 AM
NYSE : BMY
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
Bristol Myers Squibb today announced meaningful progress toward its global inclusion& diversity goals and health equity commitments, meeting and exceeding some goals ahead of schedule. In 2020, Bristol Myers Squibb and the Bristol Myers Squibb Foundation, an independent charitable organization, each committed $150 million over five years, totaling $300...
RHEA-AI
positive
03/03/23 8:00 AM
NYSE : BMY
Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)
Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb, a global biopharmaceutical company, to deploy an artificial intelligence algorithm and provider workflow software intended to identify and triage patients who may require further evaluation for the detection of...
RHEA-AI
neutral
03/03/23 6:59 AM
NYSE : BMY
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
Bristol Myers Squibb today announced that the European Commission has granted full Marketing Authorization for Reblozyl ®, a first-in-class therapeutic option, for treatment in adult patients of anemia associated with non-transfusion-dependent beta thalassemia. Reblozyl is currently approved in the European Union, United States and Canada to...
RHEA-AI
positive
03/02/23 6:59 AM
NYSE : BMY
clinical trial
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa inhibitor. “The depth and breadth of the Librexia clinical development program will capture data in...
RHEA-AI
neutral
02/28/23 6:59 AM
NYSE : BMY
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application and the European Medicines Agency has validated the Type II Variation Marketing Authorization Application for Opdivo ® as monotherapy in the adjuvant setting for the treatment of patients with completely...
RHEA-AI
neutral
02/27/23 6:59 AM
NYSE : BMY
conferences
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
Bristol Myers Squibb today announced the presentation of research supporting the company’ s cardiovascular franchise at the American College of Cardiology Annual Scientific Session& Expo together with the World Congress of Cardiology, taking place in-person and virtually March 4-6, 2023. During the meeting, the Bristol Myers Squibb-Pfizer Alliance...
RHEA-AI
neutral